Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
GlobeNewswire
· *If approved, IXCHIQ*^*®** will become the first vaccine available in the EU against the chikungunya virus (CHIKV)*
·..
· *If approved, IXCHIQ*^*®** will become the first vaccine available in the EU against the chikungunya virus (CHIKV)*
·..
Original-Research: Valneva - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH..
*Total revenues of €153.7 million, including product sales of €144.6 million*
· Product sales surpassed..